Trial Profile
A Phase I/II Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Copanlisib (Primary) ; Nivolumab (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 02 Jan 2024 Planned End Date changed from 1 Dec 2023 to 30 Jun 2025.
- 13 Jun 2023 Number of treatment arms have been increased from 2 to 3 by the addition of Experimental: Phase II/Arm B -P13K wild type /Copanlisib and Nivolumab arm. The previously existing Phase 2 arms has been labelled as Arm A.
- 01 Mar 2023 Planned End Date changed from 1 Jun 2023 to 1 Dec 2023.